US/UK/Canada

Share

Contacts

  • Probi
    Ideongatan 1A, 223 70 Lund
    +46(0)46-286 89 20
    https://www.probi.com
  • Anita Johansen

    Interim CEO & VP R&D


    +46 46 286 89 20
  • Basudha Bhattarai Johansson

    VP HR & Sustainability


    +46 46 286 89 20

    • Quotes

    A lot of virus and bacteria enter the body through the mucous membranes, where a majority of our immune system is located. Therefore, we believe that probiotics can play a vital role as delivery carrier.
    Professor Magnus Johansson
    This joint venture is an important step in our commercial efforts to address new and attractive market niches. Even in these turbulent times we see great opportunities to jointly build a successful business, based on our longstanding relationship and confidence in our respective abilities to create scientific and commercial success.
    Tom Rönnlund, CEO Probi
    “We are very excited about the results showing an opportunity to delay the progression of bone loss by using our probiotics in this healthy population, which potentially may lead to a reduced risk for osteoporosis.”
    Ole Søgaard Andersen, CEO of Probi
    We are very happy to initiate this development program together with a strong global partner in OTC. By combining Probi´s probiotic expertise with the pharma company's development resources and regulatory expertise, we will form a very strong team moving forward together.”
    Ole Søgaard Andersen CEO of Probi
    “We are proud to conclude that our largest clinical trial so far has successfully confirmed earlier clinical results. Interestingly, in subjects that did not experience any viral infection during the study period, there was an activation of the immune system measured already after 2 weeks of Probi Defendum® intake, indicating an alert and resilient immune system.”
    Peter Nählstedt, CEO Probi AB
    “It is extremely exciting to launch the new probiotic line - Probi Select™. Through the integration of Nutraceutix, Probi has established a complete probiotic offering with the Probi Premium, Probi Select and Probi LiveBac ranges. Probi is now a true “One stop shop” for any consumer goods company wanting to drive their position in the probiotic market”
    Niklas Bjärum, President Probi USA and Global Sales & Marketing Probi Group.
    I am very excited about this transforming acquisition. Nutraceutix is an excellent match for us. Probi and Nutraceutix have complementary business models, limited customer overlap and share strong entrepreneurial values. The acquision creates a strong platform to continue the growth story in the US and in the global market.
    Peter Nählstedt
    ”There has been strong growth in the North American and Asian probiotic markets the past few years. We now see a growing interest in Europe too, and our new distribution agreements clearly reflect this positive trend
    Niklas Bjärum, Vice President of Marketing & Sales
    Pick a time period -
    Tags ( Active)

    Notice of Extraordinary General Meeting in Probi AB (publ)

    Symrise AG (“Symrise”) has declared its public tender offer to the shareholders of Probi AB (publ) (“Probi”) unconditional and controls more than 90 per cent of the total number of shares and votes in Probi. Against this background, the shareholders of Probi reg. no. 556417-7540, are hereby officially convened to an Extraordinary General Meeting (“EGM”) which will be held on 13 February 2025 at 15:00 at Probi HQ, Ideongatan 1A, Lund, Sweden. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the EGM also by postal voting in accordance

    Probi applies for delisting and convenes an Extraordinary General Meeting

    On 16 January 2025, Symrise AG (“Symrise”) has declared the public offer for all shares in Probi AB (“Probi” or the “Company”) unconditional. Symrise controls more than 90 per cent of the shares in Probi and has communicated its initiation of a forced redemption (squeeze-out) of the remaining shares in the Company. Further to the initiation of the squeeze-out process, the Board of Probi has today resolved to apply for delisting of the Company’s shares from Nasdaq Stockholm. The last day of trading in the Company’s shares on Nasdaq Stockholm will be announced as soon as the Company has

    Statement from the independent bid committee of Probi in relation to the public takeover offer by Symrise

    The independent bid committee of Probi AB (publ) (“Probi” or the “Company”) unanimously recommends the shareholders of Probi to accept the cash-based public takeover offer submitted by Symrise AG (“Symrise”) on 20 November 2024.Background This statement is made by the independent bid committee of Probi pursuant to Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). On 20 November 2024, Probi’s principal shareholder and parent company Symrise announced that Symrise is making a public takeover offer to the shareholders of Probi for SEK 350 per Probi share (the “Offer”). Probi’s

    Probi’s Board comments on Symrise’s public takeover offer

    On this day 20 November 2024, Probi AB’s (“Probi”) principal shareholder and parent company Symrise AG (“Symrise”) has announced that Symrise is making a public takeover offer to the shareholders of Probi for SEK 350 per Probi share (the “Offer”). The acceptance period for the Offer is expected to commence on 18 December 2024 and end on or about 15 January 2025. For further information, please refer to Symrise’s press release, www.symrise.com/de/probi 

    Probi CFO departure

    Effective today, and by mutual agreement, Per Lindblad will leave his position as CFO at Probi AB (publ). Ulf Sköld has been appointed as interim CFO and will take over immediately, until a permanent successor has been appointed. Ulf has extensive experience as CFO from different industries such as packaging and food industry. Ulf most recently held interim CFO role at Lime Technologies. Ulf holds degree in Economics from Lund University.  "Per has been an engaged member of the management team during a year of transition, and I want to take the opportunity to thank him for the work he

    Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

    With 88 percent of U.S. adults being metabolically unhealthy[1] and over 1.9 billion adults classified as overweight worldwide[2], the need for effective metabolic health solutions is acute. To tackle one of the most critical health issues of our time, Probi is unveiling a new product concept.Metabolic health, cardiovascular support, and weight management are all key areas addressed by Metabolic Health by Probi®, the latest innovation from Probi which will be unveiled at SupplySide West 2024 during October 28–31. “Our aim is to help people take control of their microbiome, their gut, and

    Q3 2024: Tangible improvement in operations

    Important events during the third quarter · Net sales in Q3 amounted to SEK 143.7 m, corresponding to a decrease of 7.9% compared to last year (-5.1% adjusted for currency effects). · The EBITDA margin was 20.1%, corresponding to an increase of 2.0 %-points compared to last year. · Probi successfully implemented a new global ERP system, streamlining operations and enhancing efficiency across key business functions. · A new study suggests that consuming Probi's proprietary probiotic strain HEAL9[®] may serve as a potential therapeutic option for mitigating mild cognitive

    Presentation of Probi’s Q3 Report 2024

    Probi’s report for the third quarter 2024 will be published on Tuesday, 22 October at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q3-report-2024 If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. https://ir.

    Probi partners with Global BHP BrainTrust and the FINGERS Brain Health Institute to counteract dementia

    Probi today announces a research collaboration with the Global BHP BrainTrust and FINGERS Brain Health Institute (FBHI) aimed at reducing dementia risk in women, who account for two-thirds of Alzheimer’s cases. The collaboration is part of the planned FINGERS Plus for Women study."We are thrilled to be part of the FINGERS Plus for Women initiative. This collaboration represents a significant step forward in our commitment to advancing brain health and improving everyday life for people worldwide. By combining our expertise in probiotics with the innovative research approach of the Global

    Nordic launch of Probi Sense – a unique dietary supplement for the mental capacity

    Today, on World Mental Health Day, Probi launches Probi Sense, a brand-new probiotic food supplement reducing stress and improving mental well-being. The new product will shortly become available directly to consumers through pharmacies and selected retailers across Sweden, Denmark and Norway.Probi Sense contains Probi's unique and well-documented lactic acid bacteria strain Lactiplantibacillus plantarum HEAL9 (HEAL9[®]), as well as the minerals zinc, iodine and magnesium. The product, underpinned by four clinical studies demonstrating its positive effects, is designed to support mental

    New study strengthens Probi[ ][®]s L. plantarum HEAL9[®] strain in cognitive function

    A new study published in the journal Food & Function shows that Probi’s proprietary probiotic strain LPHEAL9 reduced cognitive impairment and inflammation in both the gut and brain in a mice model of Alzheimer's disease (AD). These findings confirm LPHEAL9's role in Gut-Brain health and offer hope for future preventative measures in the early stages of Alzheimer's.This is the fifth study highlighting the effects of the probiotic strain Lactiplantibacillus plantarum HEAL9 on the Gut-Brain axis, adding valuable insights into its potential for supporting everyday health. Conducted in

    Q2 2024: Significant progress on strategic initiatives

    Important events during the second quarter · Net sales in Q2 amounted to SEK 178.9 m, corresponding to an increase of 25% compared to last year (23% adjusted for currency effects). · The EBITDA margin was 19%, corresponding to an increase of 10 percentage points compared to last year. · Probi and ProViva celebrated 30 years of collaboration, highlighting the success with ProViva's popular probiotic drinks containing Lp299v[®]. · Probi strengthened its presence in APAC by launching China Innovation Day, a customer-oriented event focused on fostering collaborations in the

    Presentation of Probi’s Q2 Report 2024

    Probi’s report for the second quarter 2024 will be published on Tuesday, 16 July at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q2-report-2024 

    Probi® launches at Matas, Denmark's leading health retailer

    As the Swedish market leader in probiotic supplements, Probi AB is proud to announce that our products are now also available in Denmark, at the country's leading health-oriented retail chain, Matas. Through this collaboration, we can offer our scientifically proven probiotic solutions to a wider audience and strengthen our commitment to improving people's health and well-being in the Nordic region.In recent years, consumers' views on health have changed significantly, with an increased focus on preventive health measures and overall well-being. Interest in gut health is growing, driven by

    Probi[®] strengthens the Gut-Brain offering with new study in older adults

    The increased focus on healthy aging – to live longer and stay healthy – drives consumers to seek ways to improve their health in general but also in specific health areas like digestive, immune and mental health.Inflammaging, a newer term used to describe chronic inflammation that accompanies aging, was investigated in a recently published study. The UN has estimated that the population aged 65 years and older will continue to rise during the coming years, eventually doubling by 2050[1]. With an increased older population, the demands on the healthcare system will ultimately increase,

    Probi[®] strengthen its position in the Asia-Pacific region through strong customer collaborations

    Last week Probi launched its first China Innovation Day (CID) to strengthen our relations and collaborations with our Chinese customers. A good foundation to better serve the market and the customers with more relevant solutions to support their and the consumers’ needs.The APAC region is the largest probiotic market and stands for nearly 50% of the total global market. It is also the strongest growing market driven by China which stands for 50% of the APAC region. China is the second largest probiotic market, after US, with a value of 2 000 MUSD (2023) and with an estimated growth of 12,8%

    Probi® and ProViva celebrate 30 years of tasteful cooperation

    In 1994, the first ProViva drink was launched in Sweden, containing Probi's patented live bacteria Lactiplantibacillus plantarum 299v (LP299V®). The 30-year collaboration has proved successful, as ProViva is now one of the top three most popular brands in chilled juice. The 30th anniversary celebrations kicked off on May 7 in Rosendal's garden in Stockholm with a brunch event. In addition to Probi and ProViva's presence, the influencer duo Foodgeekz also participated, who together with other invited guests got to test their favorite flavors of ProViva.ProViva was launched 30 years ago and

    Probi´s Annual General Meeting 2024

    On Probi´s Annual General Meeting on 7 May 2024, the following was resolved:                                  · The Annual General Meeting approved the Annual Report and the Board’s proposal on a dividend for the financial year 2023 corresponding to SEK 1.30 per share. The record date was set to 10 May 2024. · The Annual General Meeting resolved to approve the Board’s remuneration report. · The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the financial year 2023. · The Annual General Meeting resolved that the Board

    Probi partners with Bower to encourage increased recycling among consumers

    Probi AB aims to improve its sustainability efforts, including reducing its carbon footprint in the world. In accordance with the UN's global goal 12 "Sustainable production and consumption", Probi AB has now started a collaboration with Bower to inspire the company's consumers to increase recycling.Bower offers a mobile application that rewards the recycling of consumer packaging at regular recycling stations. The app allows consumers to earn points for recycling packaging, and users earn more points by recycling products from the brands affiliated with Bower. The points can then be

    Q1 2024: Steady Progress in a Transitional Year

    Important events during the first quarter · Underlying sales were overall as expected, despite Q1 coming in 12% below Q1 LY (11% adjusted for currency effects) to SEK 152 m (172). The reduction compared to LY is primarily due to positive one-time effects from delayed deliveries in the Americas as a result of a severe snowstorm at the end of 2022. Additionally, APAC was affected by timing shifts in orders during the quarter. · The EBITDA margin amounted to 15% (28). Adjusted for the above-mentioned snowstorm the comparison year margin is 23%. · A new study showing synergistic

    Correction (date) Presentation of Probi’s Q1 Report 2024

    Probi’s report for the first quarter 2024 will be published on Tuesday, 23 April at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q1-report-2024 

    Correction (date) Presentation of Probi’s Q1 Report 2024

    Probi’s report for the first quarter 2024 will be published on Tuesday, 23 April at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q1-report-2024 

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media